<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466243</url>
  </required_header>
  <id_info>
    <org_study_id>JBT101-DM-001</org_study_id>
    <secondary_id>116313</secondary_id>
    <secondary_id>R21AR066286</secondary_id>
    <nct_id>NCT02466243</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corbus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corbus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in&#xD;
      adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3&#xD;
      months treatment with hydroxychloroquine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A: An interventional, double-blind, randomized, placebo-control design will be used to&#xD;
      test JBT-101 in about 22 eligible male or female subjects ≥ 18 and ≤ 70 years of age with&#xD;
      moderate-to-severe active skin-predominant dermatomyositis.&#xD;
&#xD;
      Part B: A one-year open-label design to test JBT-101 in subjects who completed Part A without&#xD;
      permanent discontinuation of study product because of safety or tolerability reasons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated open-label extension.&#xD;
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 29, 2021</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events as a measure of safety and tolerability</measure>
    <time_frame>Part A: 112-day treatment and follow-up period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) from baseline in Part A.</measure>
    <time_frame>Part A: 84-day treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events as a measure of safety and tolerability</measure>
    <time_frame>Part B: (open-label extension) 364-day treatment and follow-up period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) from baseline in Part A.</measure>
    <time_frame>Part B: (open-label extension) 364-day treatment and follow-up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported outcomes from baseline at 84 days for Part A</measure>
    <time_frame>Part A: 84-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported outcomes from baseline at 364 days for Part B</measure>
    <time_frame>Part B: 364-day treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>JBT-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.&#xD;
Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.&#xD;
Part B: Placebo twice daily on Days 1 - 365 of the OLE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JBT-101</intervention_name>
    <description>Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.&#xD;
Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE.</description>
    <arm_group_label>JBT-101</arm_group_label>
    <other_name>lenabasum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part A: Once daily on Days 1-28, then twice daily on Days 29-84.&#xD;
Part B: Placebo twice daily on Days 1 - 365 of the OLE.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Part A):&#xD;
&#xD;
          -  CDASI activity score ≥ 14;&#xD;
&#xD;
          -  No difficulty with lifting or walking, and no more than 1.5 x the upper limit of&#xD;
             normal of creatine phosphokinase or aldolase;&#xD;
&#xD;
          -  Failed at least 3 months treatment with hydroxychloroquine;&#xD;
&#xD;
          -  Stable treatment for dermatomyositis for at least 28 days before Visit 1 (Day 1).&#xD;
&#xD;
        Inclusion Criteria (Part B):&#xD;
&#xD;
          -  Completion of dosing in Part A without permanent discontinuation of study product&#xD;
             because of safety or tolerability reasons&#xD;
&#xD;
        Exclusion Criteria (Part A and B):&#xD;
&#xD;
          -  Significant diseases or conditions other than DM that may influence response to the&#xD;
             study product or safety;&#xD;
&#xD;
          -  Any one of the following values for laboratory tests at Screening:&#xD;
&#xD;
               1. A positive pregnancy test (or at Visit 1);&#xD;
&#xD;
               2. Hemoglobin &lt; 10 g/dL;&#xD;
&#xD;
               3. Neutrophils &lt; 1.0 x 10^9/L;&#xD;
&#xD;
               4. Platelets &lt; 75 x 10^9/L;&#xD;
&#xD;
               5. Creatinine clearance &lt; 50 ml/min according to modified Cockcroft-Gault equation;&#xD;
&#xD;
               6. Aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase &gt;&#xD;
                  2.5 x upper normal limit;&#xD;
&#xD;
               7. Total bilirubin ≥ 1.5 x upper limit of normal.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Principal Investigator, is clinically&#xD;
             significant and may put the subject at greater safety risk, influence response to&#xD;
             study product, or interfere with study assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria Werth, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Perlman School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Perlman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <disposition_first_submitted>January 18, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 18, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 22, 2019</disposition_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JBT-101, lenabasum, dermatomyositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

